Annual CFO
$139.80 M
+$233.59 M+249.07%
December 31, 2023
Summary
- As of February 7, 2025, TRDA annual cash flow from operations is $139.80 million, with the most recent change of +$233.59 million (+249.07%) on December 31, 2023.
- During the last 3 years, TRDA annual CFO has risen by +$165.37 million (+646.75%).
- TRDA annual CFO is now at all-time high.
Performance
TRDA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$24.27 M
-$64.10 M-160.92%
September 30, 2024
Summary
- As of February 7, 2025, TRDA quarterly cash flow from operations is -$24.27 million, with the most recent change of -$64.10 million (-160.92%) on September 30, 2024.
- Over the past year, TRDA quarterly CFO has increased by +$226.00 thousand (+0.92%).
- TRDA quarterly CFO is now -111.93% below its all-time high of $203.40 million, reached on March 31, 2023.
Performance
TRDA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$13.96 M
+$226.00 K+1.59%
September 30, 2024
Summary
- As of February 7, 2025, TRDA TTM cash flow from operations is -$13.96 million, with the most recent change of +$226.00 thousand (+1.59%) on September 30, 2024.
- Over the past year, TRDA TTM CFO has dropped by -$130.48 million (-111.99%).
- TRDA TTM CFO is now -109.99% below its all-time high of $139.80 million, reached on December 31, 2023.
Performance
TRDA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
TRDA Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +249.1% | +0.9% | -112.0% |
| 3 y3 years | +646.8% | +11.1% | +85.1% |
| 5 y5 years | +1394.3% | +11.1% | +85.1% |
TRDA Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +249.1% | -111.9% | +30.9% | -110.0% | +85.1% |
| 5 y | 5-year | at high | +249.1% | -111.9% | +30.9% | -110.0% | +85.1% |
| alltime | all time | at high | +249.1% | -111.9% | +30.9% | -110.0% | +85.1% |
Entrada Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$24.27 M(-160.9%) | -$13.96 M(-1.6%) |
| Jun 2024 | - | $39.83 M(-256.1%) | -$14.19 M(-84.1%) |
| Mar 2024 | - | -$25.52 M(+535.9%) | -$89.11 M(-163.7%) |
| Dec 2023 | $139.80 M(-249.1%) | -$4.01 M(-83.6%) | $139.80 M(+20.0%) |
| Sep 2023 | - | -$24.49 M(-30.2%) | $116.51 M(+2.6%) |
| Jun 2023 | - | -$35.09 M(-117.3%) | $113.52 M(-13.1%) |
| Mar 2023 | - | $203.40 M(-844.9%) | $130.60 M(-239.3%) |
| Dec 2022 | -$93.79 M | -$27.30 M(-0.6%) | -$93.79 M(+7.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | -$27.48 M(+52.6%) | -$87.02 M(+18.2%) |
| Jun 2022 | - | -$18.01 M(-14.2%) | -$73.62 M(+15.9%) |
| Mar 2022 | - | -$20.99 M(+2.2%) | -$63.52 M(+24.9%) |
| Dec 2021 | -$50.86 M(+98.9%) | -$20.54 M(+45.9%) | -$50.86 M(+67.7%) |
| Sep 2021 | - | -$14.07 M(+77.9%) | -$30.32 M(+86.6%) |
| Jun 2021 | - | -$7.91 M(-5.1%) | -$16.25 M(+94.9%) |
| Mar 2021 | - | -$8.34 M | -$8.34 M |
| Dec 2020 | -$25.57 M(+136.7%) | - | - |
| Dec 2019 | -$10.80 M | - | - |
FAQ
- What is Entrada Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Entrada Therapeutics?
- What is Entrada Therapeutics annual CFO year-on-year change?
- What is Entrada Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Entrada Therapeutics?
- What is Entrada Therapeutics quarterly CFO year-on-year change?
- What is Entrada Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Entrada Therapeutics?
- What is Entrada Therapeutics TTM CFO year-on-year change?
What is Entrada Therapeutics annual cash flow from operations?
The current annual CFO of TRDA is $139.80 M
What is the all time high annual CFO for Entrada Therapeutics?
Entrada Therapeutics all-time high annual cash flow from operations is $139.80 M
What is Entrada Therapeutics annual CFO year-on-year change?
Over the past year, TRDA annual cash flow from operations has changed by +$233.59 M (+249.07%)
What is Entrada Therapeutics quarterly cash flow from operations?
The current quarterly CFO of TRDA is -$24.27 M
What is the all time high quarterly CFO for Entrada Therapeutics?
Entrada Therapeutics all-time high quarterly cash flow from operations is $203.40 M
What is Entrada Therapeutics quarterly CFO year-on-year change?
Over the past year, TRDA quarterly cash flow from operations has changed by +$226.00 K (+0.92%)
What is Entrada Therapeutics TTM cash flow from operations?
The current TTM CFO of TRDA is -$13.96 M
What is the all time high TTM CFO for Entrada Therapeutics?
Entrada Therapeutics all-time high TTM cash flow from operations is $139.80 M
What is Entrada Therapeutics TTM CFO year-on-year change?
Over the past year, TRDA TTM cash flow from operations has changed by -$130.48 M (-111.99%)